Antipyrine, Oxazepam, and Indocyanine Green Clearance in Patients with Chronic Pancreatitis and Healthy Subjects

References

• Poulsen HE, Loft S. Antipyrine as a model drug to study hepatic drug-metabolizing capacity. J Hepatol 1988;6:374–82.
   PubMed Web of Science ®Google Scholar
• Shenfield GM. Influence of thyroid dysfunction on drug pharmacokinetics. Clin Pharmacokinet 1981;6:275–97.
   PubMed Web of Science ®Google Scholar
• Farrell GC. Drug metabolism in extrahepatic diseases. Pharmacol Ther 1987;35:375–404.
   PubMed Web of Science ®Google Scholar
• Sonne J, Dossing M, Loft S, Andreasen PB. Antipyrine clearance in pneumonia. Clin Pharmacol Ther 1985;37:701–4.
   PubMed Web of Science ®Google Scholar
• McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991;21:42–69.
   PubMed Web of Science ®Google Scholar
• Acheson DW, Hunt LP, Rose P, Houston JB, Braganza JM. Factors contributing to the accelerated clearance of theophylline and antipyrine in adults with exocrine pancreatic disease. Clin Sci 1989;76:377–85.
   Google Scholar
• Crom WR, Webster SL, Bobo L, Teresi ME, Relling MV, Evans WE. Simultaneous administration of multiple model substrates to assess hepatic drug clearance. Clin Pharmacol Ther 1987;41:645–50.
   PubMedGoogle Scholar
• Villeneuve JP, Huot R, Marleau D, Huet PM. The estimation of hepatic blood flow with indocyanine green: comparison between the continuous infusion and single injection methods. Am J Gastroenterol 1982;77:233–7.
   PubMed Web of Science ®Google Scholar
• Tygstrup N. Assessment of liver function: principles and practice. J Gastroenterol Hepatol 1990;5:468–82.
   PubMedGoogle Scholar
• Ott P, Keiding S, Bass L. Plasma elimination of indocyanine green in the intact pig after bolus injection and during constant infusion: comparison of spectrophotometry and high-pressure liquid chromatography for concentration analysis. Hepatology 1993;18:1504–15.
   Google Scholar
• Sonne J, Loft S, Dossing M, Vollmer-Larsen A, Olesen KL, Victor M, et al. Bioavailability and pharmacokinetics of oxazepam. Eur J Clin Pharmacol 1988;35:385–9.
   Google Scholar
• Dossing M, Volund A, Poulsen HE. Optimal sampling times for minimum variance of clearance determination. Br J Clin Pharmacol 1983;15:231–5.
   Google Scholar
• Loft S, Sonne J, Poulsen HE, Petersen KT, Jorgensen BG, Dossing M. Inhibition and induction of metronidazole and antipyrine metabolism. Eur J Clin Pharmacol 1987;32:35–41.
   PubMed Web of Science ®Google Scholar
• Andreasen PB, Greisen G. Phenazone metabolism in patients with liver disease. Eur J Clin Invest 1976;6:21–6.
   PubMedGoogle Scholar
• Mehta MU, Venkataramanan R, Burckart GJ, Ptachcinski RJ, Yang SL, Gray JA, et al. Antipyrine kinetics in liver disease and liver transplantation. Clin Pharmacol Ther 1986;39:372–7.
   PubMed Web of Science ®Google Scholar
• Peter JVSt, Awni WM. Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites. Clin Pharmacokinet 1991;20:50–65.
   PubMedGoogle Scholar
• Patwardhan RV, Johnson RF, Hoyumpa AJ, Sheehan JJ, Desmond PV, Wilkinson GR, et al. Normal metabolism of morphine in cirrhosis. Gastroenterology 1981;81:1006–11.
   PubMed Web of Science ®Google Scholar
• Sonne J, Andreasen PB, Loft S, Dossing M, Andreasen F. Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. Hepatology 1990;11:951–6.
   Google Scholar
• Sonne J, Dragsted J, Loft S, Dossing M, Andreasen F. Influence of a very low calorie diet on the clearance of oxazepam and antipyrine in man. Eur J Clin Pharmacol 1989;36:407–9.
   Google Scholar
• Hamberg O, Ovesen L, Dorfeldt A, Loft S, Sonne J. The effect of dietary energy and protein deficiency on drug metabolism. Eur J Clin Pharmacol 1990;38:567–70.
   Google Scholar
• Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996;31:47–64.
   Google Scholar
• Jorquera F, Culebras JM, Gonzalez-Gallego J. Influence of nutrition on liver oxidative metabolism. Nutrition 1996;12:442–7.
   Google Scholar
• Pantuck EJ, Pantuck CB, Kappas A, Conney AH, Anderson KE. Effects of protein and carbohydrate content of diet on drug conjugation. Clin Pharmacol Ther 1991;50:254–8.
   Google Scholar
• Kappas A, Anderson KE, Conney AH, Alvares AP. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clin Pharmacol Ther 1976;20:643–53.
   PubMed Web of Science ®Google Scholar
• Anderson KE, Conney AH, Kappas A. Nutrition and oxidative drug metabolism in man: relative influence of dietary lipids, carbohydrate, and protein. Clin Pharmacol Ther 1979;26:493–501.
   Google Scholar
• Krishnaswamy K, Kalamegham R, Naidu NA. Dietary influences on the kinetics of antipyrine and aminopyrine in human subjects. Br J Clin Pharmacol 1984;17:139–46.
   Google Scholar
• Fagan TC, Walle T, Oexmann MJ, Walle UK, Bai SA, Gaffney TE. Increased clearance of propranolol and theophylline by high-protein compared with high-carbohydrate diet. Clin Pharmacol Ther 1987;41:402–6.
   PubMed Web of Science ®Google Scholar
• Vaona B, Armellini F, Bovo P, Rigo L, Zamboni M, Brunori MP, et al. Food intake of patients with chronic pancreatitis after onset of the disease. Am J Clin Nutr 1997;65:851–4.
   PubMedGoogle Scholar
• Nakamura T, Arai Y, Terada A, Kudoh K, Imamura K, Machida K, et al. Dietary analysis of Japanese patients with chronic pancreatitis in stable conditions. J Gastroenterol 1994;29:756–62.
   PubMedGoogle Scholar
• Hebuterne X, Hastier P, Peroux JL, Zeboudj N, Delmont JP, Rampal P. Resting energy expenditure in patients with alcoholic chronic pancreatitis. Dig Dis Sci 1996;41:533–9.
   PubMedGoogle Scholar
• Loft S, Dossing M, Poulsen HE. Influence of age and consumption of tobacco, alcohol and caffeine on antipyrine clearance. Hum Toxicol 1988;7:277–80.
   Google Scholar
• Vestal RE, Norris AH, Tobin JD, Cohen BH, Shock NW, Andres R. Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking. Clin Pharmacol Ther 1975; 18:425–32.
   PubMed Web of Science ®Google Scholar
• Tsutsumi M, Lasker JM, Shimizu M, Rosman AS, Lieber CS. The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver. Hepatology 1989;10: 437–46.
   Google Scholar
• Sharer JE, Wrighton SA. Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos 1996;24:487–94.
   PubMed Web of Science ®Google Scholar
• Tranvouez JL, Lerebours E, Chretien P, Fouin-Fortunet H, Colin R. Hepatic antipyrine metabolism in malnourished patients: influence of the type of malnutrition and course after nutritional rehabilitation. Am J Clin Nutr 1985;41:1257–64.
   Google Scholar
• Sonne J. Factors and conditions affecting the glucuronidation of oxazepam. Pharmacol Toxicol 1993;73 Suppl 1:1–23.
   PubMedGoogle Scholar
• Sonne J, Dossing M, Loft S, Olesen KL, Vollmer-Larsen A, Victor MA, et al. Single dose pharmacokinetics and pharmacodynamics of oral oxazepam during concomitant administration of propranolol and labetalol. Br J Clin Pharmacol 1990;29:33–7.
   Google Scholar
• Greenblatt DJ, Divoll M, Abernethy DR, Harmatz JS, Shader RI. Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity. J Pharmacol Exp Ther 1982;220:120–6.
   Google Scholar
• Wood AJ, Vestal RE, Wilkinson GR, Branch RA, Shand DG. Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther 1979;26:16–20.
   Google Scholar
• Bach B, Hansen JM, Kampmann JP, Rasmussen SN, Skovsted L. Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet 1981;6:389–96.
   Google Scholar
• Greenblatt DJ, Divoll MK, Harmatz JS, Shader RI. Antipyrine absorption and disposition in the elderly. Pharmacology 1988;36:125–33.
   PubMedGoogle Scholar
• Sonne J, Boesgaard S, Poulsen HE, Loft S, Hansen JM, Dossing M, et al. Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. Br J Clin Pharmacol 1990;30:737–42.
   PubMed Web of Science ®Google Scholar
• Eichelbaum M, Ochs HR, Roberts G, Somogyi A. Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration. Arzneimittelforschung 1982;32:575–8.
   PubMed Web of Science ®Google Scholar